High frequency of EGFR mutations found in Asian population

February 15, 2014

Adenocarcinoma histology, female sex, never-smoking status, and Asian ethnicity have been considered the most important factors associated with EGFR mutations in non-small cell lung cancer and response to EGFR inhibitors. A recent study has found that, within the Asian population, the frequency of EGFR mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking, suggesting that mutation testing should be done on a broader basis among Asian patients with advanced adenocarcinoma of the lung.

The PIONEER study is the first prospective, multinational epidemiologic study to document the frequency of EGFR mutations in in the Asian population. The PIONEER authors found that EGFR mutations were present in 51.4% of stage IIIB or IV adenocarcinomas of the lung among 1,450 patients from seven regions of Asia. Previous reports have suggested a frequency of approximately 30% among the Asian population (compared with 20% among the white population). The findings of the PIONEER study are published in the February issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO).

The frequency of EGFR mutations was high among women (61.1%) and never-smokers (60.7%), but EGFR mutations were also common among men (44%), occasional smokers (51.6%), and previous smokers (43.2%). With regard to Asian regions, the frequency was highest in Vietnam (64.2%) and lowest in India (22.2%).

"The frequency of EGFR mutations in demographic and clinical subgroups of Asian patients in PIONEER suggests that EGFR should be considered for all patients with stage IIIB or IV adenocarcinoma of the lung in Asian populations," says first author Yuankai Shi, MD, of the Department of Medical Oncology, Cancer Institute/Hospital, Beijing, China. More widespread mutation testing would help to ensure the optimal identification and treatment of with adenocarcinomas that harbor EGFR .

Coauthors of the study include IASLC members Sumitra Thongprasert, MD, of the Department of Internal Medicine, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand; Chun-Ming Tsai, MD, of the Chest Department, Taipei Veteran's General Hospital, Taipei, Taiwan; Gerardo Cornelio, MD, of the St. Peregrine Oncology Unit, San Juan De Dios Hospital, Pasay City, Philippines; and Pan-Chyr Yang, MD, of the Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan who led the study.

Explore further: The link between TB and a gene mutation that causes lung cancer

Related Stories

The link between TB and a gene mutation that causes lung cancer

January 18, 2012
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease ...

Patients with EGFR exon 20 insertions have poorer prognosis

January 15, 2013
Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their ...

EGFR mutation not prognostic factor in non-small cell lung cancer

January 15, 2013
Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), may prolong survival of selected patients based on tumor biomarkers. The presence ...

Tumors with ALK rearrangements can harbor more mutations

April 22, 2013
The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...

Pathologists identify patterns of mutations to help inform design of future trials

March 22, 2013
Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non-small cell lung cancer (NSCLC), surgical resection remains the treatment of choice ...

Study confirms prognostic value of new IASLC/ATS/ERS adenocarcinoma sub-classification

December 15, 2012
The International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS), have proposed a new sub-classification of lung adenocarcinomas. A growing ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.